Uncategorized

Investigational cancer treatment with the potential to slow brain tumor growth is now available for patients with relapsed/refractory glioblastoma.

xCures, a healthcare data platform provider, announced that the US Food and Drug Administration (FDA) has approved an Expanded Access Program (EAP) for gallium maltolate (GaM), a new cancer therapy.

Sponsored by Imaging Biometrics, this program was set up specifically for patients with relapsed/refractory histologic or molecular glioblastoma, who have no other standard treatment options available.

The EAP is open to physicians whose patients have exhausted standard-of-care therapies, fit the eligibility criteria, and cannot access the open-enrolling phase I clinical trial for the investigation of GaM.

“This Expanded Access program will help bring GaM to patients in need while carefully monitoring patients and gathering data that will inform and improve future cancer therapies,” said Mika Newton, CEO of xCures. “Our commitment at xCures is to bridge the gap between clinical trials and patient care by harnessing the power of Real-World Evidence, which is a key step this initiative will help drive forward.”

“The opening of this EAP marks a significant milestone in our mission to combat glioblastoma,” said Michael Schmainda, president and CEO of Imaging Biometrics. “With gallium maltolate now available through the Expanded Access program, we can provide a new therapeutic option to patients who have exhausted all other avenues, offering hope and potentially extending life. Our dedication remains to advancing research and delivering solutions that can make a real difference in the fight against cancer.”

Physicians and patients can find more information about this program (NCT06404034) and how to request access at www.xcures.com/gam.

About gallium maltolate (GaM):

GaM is a novel gallium formulation that differs from gallium nitrate, a first-generation FDA-approved gallium compound that has been extensively studied in preclinical and clinical studies. The difference between GaM and gallium nitrate is that GaM has greater anti-tumor activity than Ga nitrate and can be taken orally rather than through iv administration. GaM has demonstrated promising early efficacy for patients with various malignancies.

About Expanded Access:

Expanded access is the treatment use of an unapproved drug under special forms of investigational new drug applications (IND) outside of a clinical trial by people with serious or life-threatening conditions who do not meet the enrollment criteria for the clinical trial in progress.

About the Program:

This Expanded Access program is intended to provide GaM for compassionate use in glioblastoma patients who have exhausted available therapies. The program aims to collect sufficient information about the patient’s treatment to provide a complete and accurate case report to health authorities including patients’ response and duration of response using real-world data, analysis of imaging results, an assessment of GaM safety and tolerability, and the effect of GaM treatment on patient/caregiver reported functional status and quality-of-life.

About xCures:

Launched in 2018, xCures Inc. operates an AI-assisted platform that automatically retrieves and aggregates medical records from any US care site. Data is extracted and structured within 15 minutes to offer a sophisticated view of a patient’s fully longitudinal health journey that encompasses everything from genomics to social determinants of health.

Through a variety of tools and data products, xCures provides clinically actionable, real-time insights that facilitate patients care. For more information, contact info@xcures.com or visit http://www.xcures.com.

About Imaging Biometrics:

Imaging Biometrics is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com. Follow IB on Twitter, @IQAI_IB.

Collaboration will focus on analyzing and improving guidelines-based utilization of precision medicine to better support oncologists and cancer patients. Alliance will bring together powerful analytics alongside the very best AI-driven precision oncology medical expertise.

Clarified Precision Medicine, the only company that provides oncologists with prioritized therapy options via a combination of expert medical provider review and underlying artificial intelligence (AI) computational algorithms, and xCures, a healthcare technology company that delivers real-time clinical data to power precision medicine support, today announced a strategic partnership to dramatically advance the field of precision oncology.

The two companies will come together to enhance cancer care delivery and personalized patient treatment recommendations through precision medicine and data-driven analysis. The goal of the alliance is to better identify and understand current gaps in providing precision medicine and ultimately improve patient outcomes.

Oncology faces an immediate need to improve access to precision medicine. In the United States, there are 18 million patients with a history of cancer and 1.9 million new cancer diagnoses each year. Patients who receive precision therapies have survival rates that are three times greater than those who do not. However, 75 percent of doctors say they need help interpreting the genomic tests that make precision medicine possible —which in turn leads to more effective utilization of these powerful 21st-century tools.

To that end, Clarified and xCures will collaborate on patient-level data analytics, and also work together to improve provider support, education, and communication. The two organizations will develop learning systems focused on innovative solutions in precision oncology, such as predictive analytics and treatment optimization.

Clarified will contribute its specialized treatment recommendation system to the partnership, which combines insights from experienced medical professionals with support from its AI-driven treatment algorithm. The company’s team of expert medical reviewers will provide clinical oversight. xCures will provide its AI-driven technology platform, which excels at extracting the critical information needed for care among the complex cancer patient data and enhancing access to medical records. 

“This partnership unites two of the most innovative leaders in the field of precision oncology,” said Clarified Precision Medicine CEO Rajni Natesan, MD MBA. “Clarified is the leading expert in closing gaps at the last mile of precision oncology, with an AI platform and the greatest understanding of physician needs and individual patient outcomes. xCures is a leader in data and technology that transforms clinical efficiency and patient care. This powerful alliance enables us to overcome obstacles in cancer care that can only be addressed by an advanced, data-driven understanding of oncology at the patient level.”

“We are excited to partner with Clarified Precision Medicine to harness the power of real-time clinical data and advanced analytics,” said xCures CEO Mika Newton. “This collaboration will enable us to deliver highly personalized and effective treatment recommendations, ultimately improving patient outcomes in precision oncology. By combining our strengths, we can address the critical need for better access to precision medicine and support oncologists in making data-driven decisions that enhance patient care.”

In addition to improving the utilization of precision medicine, the alliance will have significant capabilities in data collection and analytics to drive precision oncology research. The technology integration between Clarified and xCures will facilitate retrospective and prospective data analysis to improve treatment strategies and patient care outcomes.

About Clarified Precision Medicine

Clarified Precision Medicine is the first scalable molecular tumor board with a combination of an AI-based platform plus medical group, offering expert clinical somatic and pharmacogenomics consultations through its ClarifiedSelect™ and OncoGuardian™ solutions. Clarified accelerates the delivery of guidelines-based genomic insights to patients and providers by bringing together nationally recognized experts in medical oncology, oncology pharmacy, data integration, and molecular pathology who have over 100 years of collective experience in the application of precision oncology. For more information, visit: www.clarifiedprecisionmedicine.com

About xCures

Launched in 2018, xCures Inc. operates an AI-assisted platform that automatically retrieves and aggregates medical records from any US care site. Data is extracted and structured within 15 minutes, to offer a sophisticated view of a patient’s fully longitudinal health journey that encompasses everything from genomics to social determinants of health.

Through a variety of tools and data products, xCures provides clinically actionable, real-time insights that facilitate clinical research and care for patients, providers, and partners. For more information, contact info@xcures.com.

The partnership will empower patients with greater control over their health data and accelerate the discovery and approval of new treatments for kidney cancer.

The Kidney Cancer Association (KCA) has partnered with xCures, the AI-driven medical record aggregator and research company, to offer kidney cancer patients the opportunity to contribute to research through clinical trials.

Together, KCA and xCures will create an Observational Research Platform where patients can consent for their medical records to be gathered, de-identified, and organized for analysis.

Researchers collaborating with the KCA may access this unique database of real-time, regulatory-grade clinical data to support their work.

“This partnership represents a significant step forward in leveraging real-world data to accelerate the development of effective treatments for kidney cancer,” said Mika Newton, CEO of xCures. “By integrating patient records and making this comprehensive data available to researchers, we are fostering an environment where insights can be rapidly transformed into actionable therapies.”

This resource may help researchers understand which treatments show the most promise for kidney cancer patients, potentially speeding up the regulatory and approval process.

Patients who participate, as well as their providers, can also use the xCures portal to access their medical records and a care summary incorporating information from all care-providing institutions. This comprehensive summary can be shared with care providers for treatment option discussions and better decision-making.

xCures’ clinical data technology may also help patients and their providers to identify optimal treatment options and potentially match them with appropriate clinical trials.

“We are excited to partner with xCures to provide an excellent new service to patients for curated, easy-to-understand access to their health information,” said Dr. Salvatore La Rosa, KCA’s Chief Scientific Officer. “In addition, for the first time, this collaboration allows us to access real-world data, enabling us to generate evidence and determine care gaps for people with kidney cancer.”

The KCA/xCures partnership builds on xCures’ expertise in real-world oncology data and represents a joint effort to support both patients and researchers to advance kidney cancer treatment, science and pursue cures.

# # #

About xCures
Launched in 2018, xCures Inc. operates an AI-assisted platform that automatically retrieves and aggregates medical records from any US care site. Data is extracted and structured within 15 minutes, to offer a sophisticated view of a patient’s fully longitudinal health journey that encompasses everything from genomics to social determinants of health.

Through a variety of tools and data products, xCures provides clinically actionable, real-time insights that facilitate clinical research and care for patients, providers, and partners.

About the Kidney Cancer Association
The Kidney Cancer Association is a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education in order to be the universal leader in finding the cure for kidney cancer. Founded in 1990 by Eugene P. Schonfeld and a small group of patients and doctors in Chicago, Illinois, the KCA has grown into an international non-profit organization based in Houston, Texas. The KCA promotes scientific advances through two annual research symposiums and a robust grant program, participates in legislative advocacy, and seeks to be a source of education and resources for patients, caregivers, and anyone impacted by kidney cancer.

xCures’ patient-centric platform enables outcomes monitoring and evidence generation, providing insights into the best treatments, including for rare cancers.

xCures, a leading-edge healthcare technology company, is pleased to announce the presentation of two abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, to be held May 31 – June 4, at McCormick Place, Chicago, IL, USA.

The two abstracts illustrate the value of xCures’ real-time healthcare data platform. The platform’s enhanced longitudinal nationwide data goes beyond traditional retrospective real-world data, allowing for analysis of electronic medical records from partnerships with sites of care nationwide. Through its platform and patient- and observation-driven real-time datasets, xCures helps partners learn from complex and multidisciplinary therapeutic approaches to provide valuable insights to improve outcomes.

“Access to real-time, longitudinal, uninterrupted clinical data offers an unparalleled capacity to extract insights from patient medical records,” said Tim Stuhlmiller, Vice President of Scientific and Medical Affairs at xCures. “These abstracts showcase the importance of our partnerships and our platform’s incredible power to analyze outcomes and support evidence-based decisions, resulting in improved patient care.”

In one work, xCures and their partner Genome Medical, a nationwide telehealth provider of genetic services, analyzed data from patients with germline genetic testing followed by genetic counseling, including cancer risk assessment. The platform generated structured clinical data from multiple care sites to determine the percentage of patients who underwent bilateral mastectomies after receiving genetic testing and genetic counseling from Genome Medical. This is one of the first studies to use multi-institution real-world data to assess the impact of genetic counseling and genetic testing.

Half of the patients with a genetic test result that indicated bilateral mastectomy elected to have a mastectomy done after discussing this guideline-based care option with a Genome Medical genetic counselor. As evidenced in prior research, bilateral mastectomy markedly reduces the risk of breast cancer.

“Access to longitudinal records across multiple care sites allowed us to more thoroughly assess how genetic counseling and genetic testing increase the uptake of guideline-recommended cancer prevention services,” said Colleen Caleshu, Senior Director of Clinical Research at Genome Medical. “Our goal is to make genetics clinically actionable so patients can make more informed decisions about their health. By working with xCures, we are able to gain better insights into those decisions and the impact they have on the patients we serve.”

In the other abstract, xCures partnered with the FibroFighters Foundation to better understand the landscape of real-world treatments for Fibrolamellar carcinoma (FLC) by tracking treatments, molecular profiling, and outcomes. This is essential for such a rare form of liver cancer without an established standard of care.

Patients with FLC undergo extensive molecular profiling with multiple novel therapeutic regimens employed in real-world practice. Raw imaging scans are being aggregated for central radiological review to measure the depth and duration of response offered by the recorded therapeutic strategies. This dataset is a rich resource for academic and government researchers to fuel research and define optimal treatment modalities. Topline statistics for the dataset are available at https://xcures.com/flcdashboard/.

“xCures has done what no one else has been able to do for rare diseases, specifically for Fibrolamellar Carcinoma,” said Paul Kent, MD, Medical Director of the FibroFighters Foundation. “We have the largest interactive, real-time scientific database of FLC ever collected, allowing doctors from 15 countries and 27 institutions to discuss their cases with expert FLC panelists of oncologists, surgeons, radiation oncologists, interventional radiologists, and patient advocates. xCures has driven the most important advances in clinical research for FLC ever.”

Attendees of the ASCO Annual Meeting are encouraged to find Mika Newton, Max Goldstein, Tim Stuhlmiller, or Artem Petrov from xCures, who can provide in-depth insights, discuss potential collaborations, and showcase case studies from the platform’s implementation.

The abstracts presented:

Use of a nationwide, patient-powered observational platform to define the landscape of treatment, molecular profiling, and outcomes for fibrolamellar carcinoma.
Authors: Paul Kent, Alaa Awawda, Hiba Kouser, Alanis Sabates, Zachariah Cole, Mark Shapiro, Tom Stockwell, Timothy Stuhlmiller

https://meetings.asco.org/abstracts-presentations/235938

and,

Leveraging real-world data from multiple institutions to assess the rate of bilateral mastectomy after cancer genetics evaluations with genetic counselors.
Authors: Ashley Daley, Callan Russell, Timothy Stuhlmiller, Zachary Kaufman, Jill Davies, Colleen Caleshu

https://meetings.asco.org/abstracts-presentations/231790

About xCures

Launched in 2018, xCures Inc. operates an AI-assisted platform that automatically retrieves and aggregates medical records from any US care site. Data is extracted and structured within 15 minutes to offer a sophisticated view of a patient’s fully longitudinal health journey, which encompasses everything from genomics to social determinants of health.

Through a variety of tools and data products, xCures provides clinically actionable, real-time insights that facilitate clinical research and care for patients, providers, and partners. For more information, contact info@xcures.com.

USPTO awards patent for AI tech enabling virtual trials, enhancing clinical decisions through continuous learning from patient experiences.

OAKLAND, CA — xCures, Inc., a leader in health technology, is proud to announce that the U.S. Patent and Trademark Office (USPTO) has officially issued Patent No. 11,887,738, a landmark achievement in biomedical decision-making. This patent marks a significant milestone in the company’s journey to transform the value of healthcare data using artificial intelligence (AI) and deliver on the promise of precision medicine.

The newly patented technology, titled “Platforms for Conducting Virtual Trials,” introduces a novel platform for capturing clinical cases and expert-derived treatment rationales using AI to facilitate biomedical decision-making, which can include virtual clinical trials that continuously learn from the experiences of all patients, on all treatments and all the time. Algorithms such as Bayesian machine learning methods can be applied to coordinate such virtual trials. This invention demonstrates xCures’ vision for transforming US healthcare data into continuous, real-time, regulatory-grade data that can improve care, drive innovation, and accelerate the development of new treatments.

“We’re incredibly excited about this patent. The USPTO recognized our innovative work in AI-enabled learning systems using medical records plus AI to create patient case summaries, using natural language processing to create knowledge bases that support treatment selection, leveraging machine learning for personalized treatment recommendations, incorporating expert human feedback to refine algorithms, and continuous improvements via calibration from real-world outcomes data. It is just the first of many patent-pending innovations in our pipeline,” said Mark Shapiro, Chief Operating Officer at xCures.

With the issuance of this patent, xCures solidifies its position at the forefront of health data and technology. The company is dedicated to leveraging this patented technology to enable stakeholders across the healthcare continuum to implement platforms that collect, aggregate, organize, and structure healthcare data.  This approach enables continuous learning from the treatment of all patients using an AI-based platform.

The patent can be found here.

About xCures

Launched in 2018, xCures Inc. operates an AI-assisted platform that automatically retrieves and aggregates medical records from any US care site. Data is extracted and structured within 15 minutes, to offer a sophisticated view of a patient’s fully longitudinal health journey that encompasses everything from genomics to social determinants of health.

Through a variety of tools and data products, xCures provides clinically actionable, real-time insights that facilitate clinical research and care for patients, providers, and partners. For more information, contact info@xcures.com.

The company’s platform expansion transforms the value of US healthcare data by harnessing real-time, regulatory-grade data in any therapeutic area to efficiently understand the complex medical histories of patients and drive research through detailed, longitudinal datasets.

OAKLAND, CA – January 31, 2024 – xCures, a trailblazer in healthcare technology, announced today the expansion of its AI-assisted medical data platform to support real-time, regulatory-grade data in any therapeutic area. Originally designed as a tool focused specifically on cancer, the company’s platform expansion now serves as a comprehensive tool to collect and understand medical records for any US patient with any condition.

Harnessing AI/ML technology, xCures’ platform gathers records, extracts, and aggregates data, including organizing and structuring clinical, genomic, and imaging information from diverse sources, into a searchable digital record. This solution can help any user looking to quickly find or assess key clinical information about a patient for care-related activities. This integrated approach transforms how medical professionals and researchers can understand complex patients and cohort characteristics

xCures makes this technology available through software licenses to the platform and direct API connections embedded within existing healthcare workflow management platforms.  The system offers a patient-centric, longitudinal perspective crucial for informed decision-making.  

This evolution marks another advancement that will significantly benefit those making data-driven healthcare decisions.  Because the collected data can also be de-identified it can be be available for secondary research;  xCures provides the most comprehensive patient-centric longitudinal data in the form of deidentified real-world datasets that contain comprehensive insights across all providers and care locations. 

“Expanding our AI platform beyond oncology marks a significant milestone in our mission to transform the value of healthcare data,” said Mika Newton, CEO of xCures. “We’re providing access to a software platform that generates precise real-world data at the individual and cohort levels across all diseases that will accelerate groundbreaking research across many fields and directly benefit patients. ”

With its ability to aggregate and interpret diverse medical records quickly and accurately, xCures’ platform is a game-changer for anyone working to access and interpret retrospective and prospective healthcare or real-world data. It facilitates an in-depth understanding of medical patterns and conditions and enhances the scope of clinical trials and research across various diseases. Making this technology available across the healthcare ecosystem as a platform solution transforms the opportunity to leverage US healthcare data.

For more information, visit https://xcures.com/ 

About xCures

Launched in 2018, xCures Inc. operates an AI-assisted platform that automatically retrieves and aggregates medical records from any US care site. Data is extracted and structured within 15 minutes, to offer a sophisticated view of a patient’s fully longitudinal health journey that encompasses everything from genomics to social determinants of health.

Through a variety of tools and data products, xCures provides clinically actionable, real-time insights that facilitate clinical research and care for patients, providers, and partners. For more information, contact info@xcures.com or visit http://www.xcures.com.

###

Partnership now includes access to five comprehensive oncology datasets, enhancing real-world evidence in cancer research.

In the realm of oncology research, diverse, comprehensive, and fully longitudinal datasets are invaluable. They offer a granular view of patient journeys throughout the US, enabling researchers to draw clinically relevant insights.

These comprehensive datasets are crucial for advancing personalized treatment strategies and improving patient outcomes in cancer care.

The challenge in current oncology outcomes research lies in the fragmentation of patient data across numerous healthcare providers and sites of care. This creates significant gaps in understanding patient outcomes and treatment efficacies. The scattered data landscape hinders the development of robust real-world evidence (RWE) necessary for impactful cancer research.

xCures consolidates and structures clinical, genomic, and imaging data directly from patients’ electronic medical records, healthcare providers, and other sites of care along the patient’s care journey.

The broad, longitudinal, patient-centric view enables researchers and clinicians to access up-to-date and comprehensive information, paving the way for more informed and timely treatment decisions.

In addition to contributing data to support Aetion’s collaboration with the Food and Drug Administration, the new partnership enables Aetion®, a global leader in RWE and analytics, to incorporate xCures’ breast cancer, glioma, melanoma, colorectal cancer, and ovarian/uterine cancer datasets into their Accelerated Access Oncology Program.

“We’re thrilled about this partnership with Aetion,” said Mika Newton, xCures CEO. “It’s a testament to the power of collaborative efforts in advancing oncology research. By bringing our real-time, regulatory-grade, clinical data (RRC) to a broader audience, we’re not just sharing information – we’re empowering a shift towards more effective, patient-centric cancer treatments.”

Wendy Turenne, Senior Vice President, Real World Data & Operations at Aetion, said: “We are delighted to partner with xCures, as their datasets provide a unique lens into the patient’s experience. In combination with Aetion® Substantiate, these data can be analyzed in novel ways and shorten the time to generate and deliver critical insights that will help shape the future of cancer treatment.”

Contact us today for more information on how this partnership can empower your research and development strategies.

About xCures

Since 2018, xCures Inc. has operated an AI-assisted platform that automatically retrieves and aggregates medical records from all US care sites. Data is extracted and structured within 15 minutes to offer a sophisticated view of a patient’s fully longitudinal health journey that encompasses everything from genomics to social determinants of health.

Through a variety of tools and data products, xCures provides clinically actionable, real-time insights that facilitate clinical research and care for patients, providers, and partners. For more information, contact info@xcures.com, or visit http://www.xcures.com.

About Aetion®

Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. Aetion’s suite of real-world data analytics applications analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs healthcare’s most critical decisions—what works best, for whom, and when—to guide product development, commercialization, and payment innovation. Learn more at aetion.com and follow us at @aetioninc.

AWS cloud configurations will help xCures customers to leverage the company’s robust data gathering and structuring services while maintaining secure, private ownership of their data.

xCures, a trailblazer in healthcare technology is proud to offer its platform as a clinical data extraction service in AWS Marketplace, a digital catalog with thousands of software listings from independent software vendors that make it easy to find, test, buy, and deploy software that runs on Amazon Web Services (AWS).

The xCures platform is a real-time clinical data and evidence-generation tool. It is designed to securely collect complete, longitudinal medical records from virtually all US sites of care. Further, the platform automates the processing of patient records into both standardized, structured datasets (i.e., the most commonly requested FHIR format resources) and semantic interpretations of patient cases.

The Platform can gather data across care settings (including sendout labs), even when subjects change providers, insurance plans, or locations. The data is structured into de-identifiable, tokenizable representations desired by industry and stored in xCures’ multi-tenant data and evidence generation private cloud platform. This allows clients to transition from having data rights to having data assets.

All structured data is completely source-verifiable (i.e., can be traced to a clinical record) and can be gathered (or refreshed) and analyzed in minutes. The Platform is also equipped with cutting-edge Natural Language Processing (NLP) technology to assist human annotation. This ensures that output data is primed for specialized analyses or applications, even when there are custom abstraction requirements.

Mika Newton, CEO of xCures, expressed his enthusiasm about the AWS Marketplace listing, stating, “By aligning with AWS, we’re reaffirming our commitment to offering clients enhanced security and scalability. By leveraging the power of AWS, our clients can be confident that their data remains shielded by the finest digital and physical security mechanisms.”

This latest offering is a testament to xCures’ unwavering dedication to revolutionizing healthcare data accessibility, management, and security. With the Cures Platform in AWS Marketplace, the future of clinical data use looks brighter than ever.

Visit xCures’ listing in AWS Marketplace to get started; or learn more about xCures and AWS here.

About xCures

Since 2018, xCures Inc. has operated an AI-assisted platform that automatically retrieves and aggregates medical records from all US care sites. Data is extracted and structured, within 15 minutes, to offer a sophisticated view of a patient’s fully longitudinal health journey that encompasses everything from genomics to social determinants of health.

Through a variety of tools and data products, xCures can provide clinically actionable, real-time insights that facilitate clinical research and care for patients, providers, and partners. For more information, contact info@xcures.com.

xCures offers unparalleled access to data and the xINFORM patient portal to accelerate pancreatic cancer research and improve patient care

OAKLAND, CA – xCures, a leader in real-time clinical data technology, is thrilled to announce a pivotal partnership with the Pancreatic Cancer Action Network (PanCAN).

As part of the agreement, PanCAN’s researchers and grantees will have unparalleled access to xCures’ deidentified Real-time, Regulatory-grade Clinical data. 

This collaboration aims to drive innovations and breakthroughs in pancreatic cancer research by harnessing the power of real-time patient data. xCures database boasts fully longitudinal clinical data from thousands of pancreatic cancer patients, including over 25,000 locations and ~4,000 medical records per patient.

The benefits of this partnership extend beyond the research community. xCures is making their xINFORM patient portal available to PanCAN’s leading Patient Services program.

The state-of-the-art portal aggregates and centralizes patients’ medical records and structures them into a computable format and an easy-to-understand longitudinal timeline. 

The xINFORM portal supports patients in being matched with suitable treatments and clinical programs, obtaining invaluable second opinions.

Sudheer Doss, Ph.D., Chief Business Officer of PanCAN, shared his enthusiasm for the partnership: “We’re always in search of innovative ways to serve our patient community better and accelerate pancreatic cancer research. As part of the comprehensive free services we offer through our PanCAN Patient Services program, this platform can pave the way for identifying optimal treatments and ensuring that our patients receive the best care possible.”

The PanCAN-xCures partnership blends the strengths of both organizations to advance patient outcomes and bolster research capabilities.

“We at xCures are deeply committed to placing patients at the forefront of all our endeavors,” said Mika Newton, CEO of xCures. “This new partnership with PanCan is a testament to our dedication to advancing patient-centric solutions and strengthening our bond with patient advocacy organizations. Together, we will usher in a brighter, more hopeful future for all.”

About xCures

xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. 

The (unstructured) data is aggregated and organized into a powerful, up-to-date care summary that helps cancer patients get the right therapy at the right time. 

The platform’s portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions. 

The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. 

For more information, contact info@xcures.com or visit http://www.xcures.com.

About PanCAN

The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients. PanCAN takes bold action by funding life-saving research, providing personalized patient services and creating a community of supporters and volunteers who will stop at nothing to create a world in which all pancreatic cancer patients will thrive. For 18 years in a row, PanCAN has earned a Four-Star Rating from Charity Navigator – the highest rating an organization can receive. This rating designates PanCAN as an official “Give with Confidence” charity, indicating strong financial health, ongoing accountability and transparency.

New study will collect, organize, and share data for Diffuse Midline Glioma (DMG) and Diffuse Intrinsic Pontine Glioma (DIPG) research.

xCures, a leader in data-driven cancer solutions, is thrilled to announce that its platform has been highlighted as a new commitment to deliver progress on the mission of the White House Cancer Moonshot – ending cancer as we know it.

The xCures health-data technology platform has been designed to overcome a key challenge for many rare diseases: collecting, organizing, and standardizing comprehensive data from patients across the US.

In alignment with the Cancer Moonshot Initiative’s goals to reduce cancer death rates by 50% over the next 25 years, xCures is launching an ambispective natural history study of DMG and DIPG. This study will speed up the identification of patterns that can inform more personalized treatment plans and targeted therapies.

xCures will provide access without licensing fees to the data for academic and government researchers. Open access to this valuable resource will accelerate scientific breakthroughs and foster a community actively seeking a cure.

“We recognize that collaboration is key to success. Our pledge extends to fostering an ongoing relationship with all stakeholders – patients, families, physicians, researchers, and advocacy organizations,” said Mika Newton, CEO of xCures. “Together, we can create a powerful collective dedicated to advancing the understanding and treatment of DMG DIPG.”

DMG and DIPG patients are encouraged to sign up for the study at www.xcures.com/dmg

About xCures

xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, always up-to-date care summary that helps cancer patients get the right therapy at the right time.

The platform’s portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions. The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. For more information, contact info@xcures.com

Seamless integration with existing healthcare infrastructures drives unprecedented possibilities to improve medical research and patient care.

xCures, a trailblazer in healthcare technology, is delighted to unveil xUTILITY, a solution poised to transform the patient registry paradigm in the United States.

xUTILITY establishes an instantaneous patient registry platform by retrieving records nationwide and automatically digitizing and structuring the electronic health data into a common data model with AI-enhanced abstraction and source verification, as needed.

In order to provide a 360-degree view of patient health, xUTILITY includes comprehensive capture capabilities for Electronic Health Records (EHR) and Social Determinants of Health (SDOH) data.

“The integration of research and care is the future of healthcare,” said Mika Newton, CEO of xCures. “xUTILITY brings this future to the present by delivering rich, comprehensive, and timely patient data. This connectivity will spur personalized, efficient care and groundbreaking medical discoveries.”

The platform’s ability to capture Real-Time, Regulatory-Grade Clinical Data (RRC) is pivotal to delivering quality patient care and pursuing groundbreaking medical research. 

xUTILITY’s distinctive feature is its ability to accommodate user document uploads, integrated with automated data extraction. 

The resulting synchronized data architecture introduces a new era of research-driven patient care. Its innovative data extraction process, bolstered by a complete data annotation workflow, adheres to 21 CFR Part 11, signifying xCures’ unyielding commitment to data integrity.

The unprecedented level of automation offered by xUTILITY translates to a remarkable workforce multiplier, with up to a 30-fold improvement in efficiency of data curation. This efficiency enables healthcare organizations to expedite decision-making, improve health outcomes, and enhance operational effectiveness.

With xUTILITY, xCures is charting a course toward a future where the integration of research and care forms the backbone of healthcare delivery.

About xCures

xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, always up-to-date care summary that helps cancer patients get the right therapy at the right time.

The platform’s portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions.

The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. For more information, contact info@xcures.com.

xCures data deemed fit-for-purpose to address research questions relevant to the prevention, clinical care, diagnostics, and treatment in oncology.

First posted on NewsDirect

In a step forward for healthcare research, xCures is pleased to announce that it will support Aetion®’s collaboration with the US Food and Drug Administration (FDA) Oncology Center of Excellence (OCE). As part of this partnership, xCures will provide Aetion with data to support their research collaboration agreement with OCE which centers on using real-world data (RWD) to assess real-world oncology endpoints and measure and address health disparities.

As part of the collaboration with OCE, Aetion’s comprehensive fit-for-purpose data assessment identified xCures’ real-time, regulatory-grade data platform to be an appropriate fit for this research study, particularly its ability to integrate clinical data with patient pathology, radiology reports, and imaging assessments.

“Aetion is proud to embark on this partnership with xCures to help OCE conduct pivotal research to advance the use of real-world evidence, including in measuring and understanding vulnerable and underrepresented populations,” said Liz Garry, Head of Scientific Research, Aetion. “This work furthers our mission to power critical decisions in healthcare with data science-driven technology and brings us one step closer to achieving health equity.”

xCures’ CEO, Mika Newton, explains, “Our platform’s automated organization and structuring of aggregated, continuous data result in complete, source-verifiable, and fully longitudinal clinical data sets. This rich dataset can offer unprecedented insight into the real-world patient experience.”

The contribution of robust RWD from xCures will play an integral role in this endeavor, aiming to fill knowledge gaps and facilitate advancements in healthcare research. For more information about real-time, regulatory-grade clinical data, please visit www.xcures.com/solutions.

About Aetion®
Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs healthcare’s most critical decisions—what works best, for whom, and when—to guide product development, commercialization, and payment innovation. Learn more at aetion.com and follow us on LinkedIn.

About xCures
xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, always up-to-date care summary that helps cancer patients get the right therapy at the right time.
The platform’s portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions.

The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials.

xCures’ technology harnesses real-time patient data and makes it accessible for scientific exploration and to improve patient options.

Today, xCures and the Diffuse Intrinsic Pontine Glioma (DIPG) / Diffuse Midline Glioma (DMG) Research Funding Alliance (DDRFA) are proud to announce their partnership, a collaboration focused on leveraging real-time patient data to drive forward DMG (including DIPG) scientific study and patient care options.

Through this collaboration, xCures aims to streamline DMG research and enhance patient care by centralizing the collection and analysis of anonymized DMG patient data. By enhancing scientific discovery while upholding patients´ and doctors´ stringent privacy and security standards, this partnership will significantly advance patient-driven research and treatment options.

“We’re incredibly excited to join forces with xCures,” said Lisa Ward, coordinator for DDRFA. “Through this collaboration, we’re leveraging cutting-edge technology to elevate DIPG and DMG research. Our vision is to learn from every patient in real-time, aggregate this vital data, and make it accessible for further scientific exploration. Equally as important, is to structure data to be widely accessible to academic researchers and industry poised to bring discoveries in this nearly universally fatal childhood cancer.”

xCures, renowned for its technology solutions in oncological clinical research, will provide a secure platform for data gathering and analysis. Their unique ‘Privacy by Design’ approach ensures patient data privacy, a crucial element of this partnership, and thus facilitates the creation of an extensive, dynamic dataset that reflects the real-world experiences of DMG patients. Moreover, the dataset’s continuous updates will offer researchers timely insights into treatment responses, symptom progression, and patient outcomes.

“Collaborating with DDRFA will permit us to apply our technology towards a critically important cause,” commented Mika Newton, the CEO of xCures. “We believe this partnership will have a crucial role in advancing DIPG and DMG research, and ultimately improving patient care.”

By fostering a more profound understanding of DIPG, xCures and DDRFA strive to spark scientific breakthroughs and inform treatment decisions, significantly improving the prognosis for patients living with this devastating disease.

Patients and caregivers that want to help and leverage the power of this collaboration are encouraged to visit www.xcures.com/dmg

About DDRFA
DDRFA is a leading not-for-profit alliance of over 60 separate foundations and funds dedicated to the research and advocacy of Diffuse Intrinsic Pontine Glioma (DIPG) and Diffused Midline Glioma (DMG). Its mission is to drive forward scientific understanding and treatment options for DIPG and DMG through fostering collaborative research efforts and increasing public awareness. DDRFA is coordinated by Tough2gether Foundation. Many of its member organizations are founded by families in memory of children lost to DIPG and DMG. Together the members fund cutting-edge research because they know well that young lives depend on them. For more information, visit www.ddrfa.org

About xCures
xCures Inc. operates an AI-assisted platform that offers patients and oncologists access to all their medical records, irrespective of where they were treated, an always up-to-date comprehensive Care Summary, and a Treatment Options Report. This service is free and designed to help all cancer patients get the right therapy at the right time.

The fully longitudinal (unstructured) patient clinical data is aggregated and organized for use by life sciences professionals in studies and decentralized trials. For more information, visit www.xcures.com

CureMatch will leverage the xCures technology that automatically creates a comprehensive outline of a cancer patient’s medical history in order to improve treatment recommendations.

CureMatch, Inc., a healthcare technology company that leverages artificial intelligence (AI) to power precision medicine support for oncology, is proud to announce a partnership with xCures, Inc., to connect cancer patients and physicians with optimal investigational or approved therapies. CureMatch will leverage the xCures technology platform to create a comprehensive outline of a cancer patient’s medical history and further enhance its precision cancer treatment recommendation capabilities.

CureMatch analyzes an individual patient’s genetic sequencing report to determine which drug combinations, out of the millions possible, could most effectively treat their cancer. It then provides oncologists with clear, accessible, predictive treatment analysis in an easy-to-read report that equips them with actionable knowledge tailored for each unique case. With xCures, cancer patients get immediate access to their care summary and all of their medical data in one easy-to-access place, greatly facilitating the finding of promising treatment options, even as they seek second opinions and try new therapies.

The collaboration between CureMatch and xCures will give oncologists clear, comprehensive access to patient records and past treatments, enabling them to make more informed recommendations for combination precision cancer treatments based on the CureMatch report.

“The collaboration between xCures and CureMatch brings together two leading companies at the forefront of digital healthcare innovation,” said Mika Newton, CEO of xCures. “By combining our strengths, we are confident that we can accelerate the adoption of precision oncology and improve outcomes for cancer patients globally.”

“This partnership represents a significant step forward in harnessing the power of AI technology to optimize cancer care,” said Navid Alipour, CEO of CureMatch. “By combining xCures’ patient medical history platform and our treatment-matching algorithm, we can make the process of obtaining genetically tailored, precision cancer therapies a reality for more patients.”

About CureMatch®

CureMatch is a leader in precision medicine digital solutions. Created on the belief that oncologists everywhere should benefit from world-class research, the CureMatch Decision Support System helps guide oncologists in the selection of cancer drugs that are customized for individual patients based on the molecular profile of their tumor, allowing each oncologist to become an expert in personalized medicine for better patient outcomes. www.CureMatch.com

About xCures

xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, always up-to-date care summary that helps cancer patients get the right therapy at the right time.

The platform’s portals, xINFORM for patients and xDECIDE for providers, provide scientific and medical rationales for all treatment options.

The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials.

For more information, contact info@xcures.com or visit our homepage.

Real-world patient data gives valuable insights, such as collecting data on rare cancers and showing real-world side effects of treatment combinations. 

[Oakland, CA, May 26, 2023] – xCures, a healthcare technology company, is pleased to announce its participation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023, to be held from June 02 – 06, 2023, at McCormick Place, Chicago, IL USA.  

The two abstracts accepted showcase the capabilities of its real-time clinical data platform to support patient care. The abstracts illustrate the platform´s enhanced longitudinal nationwide data beyond existing traditional retrospective real-world data (RWD) and how its platform can prospectively track clinical outcomes for (rare) cancer patient populations and structure clinical data for decision support.

“Access to real-time, longitudinal, uninterrupted clinical data offers an unparalleled capacity to extract insights from patient medical records,” said Tim Stuhlmiller, Vice President of Scientific and Medical Affairs at xCures, “these abstracts showcase our ability to utilize real-world data to improve patient care today, rather than 2-5 years from now.”

The xCures data platform, powered by a connection to the health information exchange and structured FHIR and CCDA data direct from institutional EMRs, has enabled a nationwide analysis of glioblastoma therapeutic combinations.

Under the guidance of Dr. Michael Castro of the Beverly Hills Cancer Center, a potentially practice-changing detrimental effect of proton pump inhibitors in glioblastoma was unveiled. This data is critical since up to 60% of brain cancer patients are prescribed these drugs, which could easily be exchanged for drugs with a different mechanism of action.

In a second abstract, xCures supports Dr. Paul Kent and the FibroFighters advocacy group to implement a multidisciplinary, international tumor board for fibrolamellar carcinoma, a rare adolescent and young adult cancer.

This tumor board is one of the world´s few international virtual tumor boards and the first ever for fibrolamellar carcinoma, offering patients a free consultation from leading experts. The xCures outcomes database provides actionable clinical data to guide decision-making in the tumor board. In addition, the platform collects outcomes prospectively to close the learning loop and improve future recommendations of the board.

Attendees of the ASCO Annual Meeting are encouraged to find Tim Stuhlmiller, Mark Shapiro, and Max Goldstein from xCures, who can provide in-depth insights, discuss potential collaborations, and showcase case studies from the platform´s implementation.

The abstracts presented:

Use of proton pump inhibitors (PPI) in glioblastoma (GBM) and relationship to overall survival in a national real-world evidence (RWE) database.

Authors: Michael Castro, Jameson Quinn, Asher Wasserman, Mark Shapiro, Timothy Stuhlmiller, Santosh Kesari

https://meetings.asco.org/abstracts-presentations/223217

and,

Clinical utility of an international multidisciplinary virtual tumor board for fibrolamellar carcinoma.

Authors: Paul Kent, Jordan Tasse, Erik Schadde, Tomoaki Kato, Abhinav Humar, Oliver Fisher, Matthew Dixon, Darrell Yamashiro, Albert Cornelius, Nelson Royall, Thomas Kim, Julie Friedland, Timothy Stuhlmiller, Alaa Awawda, Alanis Sabates, Mark Shapiro, Jessica Ellison, Tom Stockwell

https://meetings.asco.org/abstracts-presentations/224077

About xCures

xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, always up-to-date care summary that helps cancer patients get the right therapy at the right time.

The platform´s portals, xINFORM for patients and xDECIDE for providers, provide scientific and medical rationales for all treatment options. The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials.

For more information, contact info@xcures.com or visit http://www.xcures.com.

Genome Medical and xCures have joined forces to provide patients with a new level of personalized care. Through this collaboration, Genome Medical’s genetic counselors will have access to xCures’ comprehensive care summaries for patients based on electronic medical records from across the healthcare ecosystem. This information will be used to better inform the treatment of Genome Medical patients.

Genome Medical’s national reach and industry-leading genetic counseling services deliver critical insights and care to patients as they understand the risk factors and genetic implications of their conditions.

“Together, we are delivering the knowledge and data that is vital for precision medicine,” said Mika Newton, CEO of xCures. “Our real-time clinical data offers unique insights for patients and providers in their fight against cancer.”

“We look forward to collaborating with xCures to deliver an enhanced level of care to our patients and with an even more complete view of the patient’s health background,” said Jill Davies, CEO of Genome Medical. “This collaboration will have a great impact on the patients we serve, with the potential for an even greater impact on population health through enhanced research for oncology and other inherited diseases.”

Incorporating xCures’ real-world clinical data into the comprehensive Genome Medical genetic counseling sessions is another example of both companies’ mission to help integrate powerful genetic insights into a patient’s health journey.  It brings to life the promise of genomic medicine, making genetic information clinically actionable for patients and their providers while supporting providers in their efforts to deliver genetic services at-scale.

The companies will also collaborate with researchers to use the aggregated knowledge gathered from this initiative to further research and treatment that has the potential to improve care and outcomes across care settings. With this exciting new collaboration, Genome Medical and xCures are revolutionizing patient care and shaping the future of connected health.

About xCures

xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from any institution a cancer patient visited and organizes them into a powerful care summary. This summary facilitates the generation of treatment options reports and connects cancer patients and their physicians with optimal approved or investigational therapies. The platform prospectively generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. For more information, contact info@xcures.com or visit http://www.xcures.com.

About Genome Medical

Genome Medical, the leading telegenetics care delivery company, is making genetic care accessible and actionable for patients through seven-day a week access to genetic services. By partnering with health systems, providers, labs and biopharmaceutical companies, Genome Medical expands the reach and impact of genomic medicine. The company helps its partners deliver clinical risk assessments for patients, genetic test recommendations and ordering, pre and post-test genetic counseling through its team of expert genetic counselors and personalized care plans. Headquartered in South San Francisco, Genome Medical has been honored as “The Best Digital Health Company to Work For” by Rock Health and the “Top 50 in Digital Health” by Fenwick & West and Goldman Sachs. To learn more, visit genomemedical.com and follow @GenomeMed.

RenovoRx’s Phase III clinical study is open to pancreatic adenocarcinoma patients and focuses on extending overall survival and improving quality of life.

[EINPresswire] xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as pancreatic adenocarcinoma. Through this collaboration, xCures will help eligible pancreatic cancer patients access a Phase III clinical study entitled, Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer (TIGeR-PaC).

The primary focus of the TIGeR-PaC study is to administer targeted therapy to pancreatic cancer patients safely and without transmission to non-targeted areas. The end goals are to determine whether this targeted method of delivering chemotherapy can extend survival while also improving quality of life.

Although pancreatic cancer treatment has improved, pancreatic cancer patients continue to have poor outcomes – partially due to the tissue surrounding the tumor hampering intravenously delivered chemotherapy drug access to the cancer cells. Unlike intravenous (systemic) chemotherapy, RenovoRx’s technology delivers chemotherapy directly to the pancreas via an artery close to the tumor. RenovoRx designed this technology based on evidence that administering chemotherapy in this way may shrink or stabilize certain types of cancer. In fact, studies have demonstrated that gemcitabine (an FDA-approved chemotherapy) administered directly via the pancreatic arteries may be associated with more than half the patients living over two years.

“As the RenovoRx team looks forward to reporting the first prospective interim analysis for the TIGeR-PaC study, expected in the beginning of 2023, we are pleased to partner with xCures to aid additional pancreatic cancer patients gain access to our study,” said Shaun Bagai, CEO of RenovoRx. “Our therapy platform is challenging the standard-of-care treatment (systemic chemotherapy) available to locally advanced pancreatic cancer (LAPC) that is often associated with debilitating side effects for patients.”

Mr. Bagai added, “Results of Phase I/II and observational registry studies suggest that the RenovoRx therapy platform may enhance patient survival while countering chemotherapy tolerability issues. The result could be more time for patients with their loved ones and improved quality of life.”

“We are thrilled to partner with RenovoRx and help more pancreatic cancer patients gain access to the TIGeR-PaC clinical study,” said Mika Newton, CEO of xCures. “We hope our combined efforts will improve recently diagnosed pancreatic cancer patient’s health and quality of life outcomes.”

The TIGeR-PaC study is open to adults recently diagnosed with pancreatic adenocarcinoma that has not spread to other body parts and cannot be treated surgically. If you are interested in signing up for the study, click here. Once you do so, a member of the xCures study team will assist you through the screening and enrollment process if you are eligible.

About xCures

xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from any institution a cancer patient visited and organizes them into a powerful care summary. This summary greatly facilitates the generation of treatment options reports and connects cancer patients and their physicians with optimal approved or investigational therapies. The platform’s portals, xINFORM for patients and xDECIDE for providers, provide scientific and medical rationales for all treatment options. The platform prospectively generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. For more information, contact info@xcures.com.

About RenovoRx

RenovoRx is a clinical-stage biopharmaceutical company with a vision to disrupt the current paradigm of cancer treatment. The company’s mission is to lead a revolution in oncology therapy by delivering its innovative and targeted intra-arterial (IA) delivery of chemotherapy directly to solid tumors. The proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP^®)  therapy platform aims to avoid the harsh side effects typical of the current standard of care, thus improving patient well-being and extension of life so more time may be enjoyed with loved ones. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. RenovoRx’s lead product candidate, RenovoGem^TM, is a combination of gemcitabine and our patented delivery system, RenovoCath^®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase III TIGeR-PaC trial for the treatment of LAPC.

RenovoRx’s patent portfolio for its therapy platform and product candidates includes seven U.S. patents, one European patent and several additional patents pending in the US, EU and Asia. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer.

Learn more by visiting the RenovoRx website or following us on Facebook, LinkedIn and Twitter.

xCures, a Real-Time Regulatory Grade Clinical Data (RRC) platform, will be joining Aetion, a global real-world evidence software and analytics provider, and a group of leading diverse partners in Aetion’s launch of the Coalition for the Advancement of RWE through Randomized Controlled Trial Emulation (CARE) Initiative.

Aetion’s initiative will focus on better understanding the regulatory questions that can be answered using RWE and randomized controlled trials (RCTs), and when and why RWE and RCTs might yield the same or different results. It will conduct multiple trial emulations in various data sources, beginning with a one-year focus on oncology. Using the Aetion Evidence Platform, the Initiative will help identify when and how RWE can support the goals of advancing efficient access to medication and improving patient care.

“xCures has implemented real-time access to retrospective and prospective medical data, including the knowledge captured in unstructured notes and images, through a regulatory grade platform,” said Mika Newton, CEO of xCures. “This transforms the nature and scope of our understanding of patient outcomes and is critical to rapidly advancing research and care.” 

Other partners joining xCures in building this relationship with Aetion include AbbVie, Amgen, AstraZeneca, Bayer, Baylor College of Medicine, Brigham and Women’s Hospital and Harvard Medical School, ConcertAI, Duke-Margolis Center for Health Policy, Friends of Cancer Research, Gilead, Loopback Analytics, Pfizer, Reagan-Udall Foundation, Tempus, TriNetX,

For additional information, visit https://aetion.com/resources/care-initiative/

About Aetion

Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. The Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs healthcare’s most critical decisions—what works best, for whom, and when—to guide product development, commercialization, and payment innovation. Learn more at aetion.com and follow us at @aetioninc.

About xCures

xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from any institution a cancer patient visited and organizes them into a powerful care summary. This summary greatly facilitates the generation of treatment options reports and connects cancer patients and their physicians with optimal approved or investigational therapies. The platform’s portals, xINFORM for patients and xDECIDE for providers, provide scientific and medical rationales for all treatment options. The platform prospectively generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. For more information, contact info@xcures.com.

XCELSIOR registry showcases its power in using real-world datasets and clinical outcomes to aid decision-making and treatment options for CNS cancer patients.

[EIN Presswire] Today, xCures announced that they will present two posters at the 27th Annual Meeting of the Society for Neuro-Oncology, from the 16th to the 20th of November 2022, in Tampa Bay, Florida.

The Society for Neuro-Oncology is a multidisciplinary society of healthcare professionals dedicated to promoting advances in neuro-oncology through research and education. Their annual meeting features research and educational sessions on brain tumors, including the latest on diagnosis and treatments.

The two xCures posters will be presented at the Poster Session on Friday, November 18, 2022, from 7:30 pm-9:30 pm EST, and are entitled:

EPCO-10: Systems biology-based therapeutic predictions with gbmSYGNAL and clinical correlates in the real-world longitudinal outcomes registry XCELSIOR

Timothy J. Stuhlmiller, Serdar Turkarslan, Julie C. Friedland, Asher Wasserman, Jameson Quinn, Zac Cole, Alaa Awawda, Sabrina Irizarry, Sebastian Williams, Mark Shapiro, Santosh Kesari, Anoop P. Patel, Nitin S. Baliga

BIOS-03: Real world clinical outcomes of patients with diffuse midline glioma in a longitudinal outcomes registry

Timothy J. Stuhlmiller, Asher Wasserman, Jameson Quinn, Zac Cole, Alaa Awawda, Sabrina Irizarry, Sebastian Williams, Mark Shapiro, Al Musella, Santosh Kesari

“I’m proud to present these analyses of real-world data and clinical outcomes of CNS cancer patients from our observational registry,” stated xCures’ VP of Scientific and Medical Affairs Timothy J. Stuhlmiller. “Together with leading neuro-oncologists and computational biologists, we are bringing evidence-based insights to the treatment of brain cancer patients.”

The xCures platform generates Real-time, Regulatory-grade, Clinical data (RRC). It now includes data on over 1,000 brain cancer patients, permitting real-time insight into which treatments show the most promise across patient cohorts.

Emerging data on investigational and off-label interventions will be presented for patients with diffuse midline glioma (DMG), along with data from a partnership with the Institute of Systems Biology (ISB) integrating real-world clinical outcomes with a systems biology algorithm for treatment predictions to identify rational treatment options for glioblastoma patients.

Posters will be available for viewing digitally at https://xcures.com/publications/ on Friday, November 18, 2022, at 7:30 pm EST.

About xCures

xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from any institution a cancer patient visited and organizes them into a powerful care summary. This summary greatly facilitates the generation of treatment options reports and connects cancer patients and their physicians with optimal approved or investigational therapies. The platform’s portals, xINFORM for patients and xDECIDE for providers, provide scientific and medical rationales for all treatment options. The platform prospectively generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. For more information, contact info@xcures.com

Recent changes to patients’ data rights enable xCures’ platform to automatically retrieve patient medical records from institutions and generate powerful care summaries.

EINPressWire, 11/8/22

Last month, the 21^st Century Cures Act forced healthcare organizations to provide patients quick and easy access to their health records in a digital format.

In response to the news, xCures is happy to announce that patients using their platform, can now automatically retrieve their medical records from the institutions where they received care, and get instant access to a powerful care summary. For free.

“The xINFORM Care Summary is extremely useful for patients and physicians. The power lies in the underlying structuring of data” said Mika Newton, CEO of xCures. “Cancer is personal, and our A.I.-powered platform uses the systematically structured data to improve the quality of healthcare encounters, identify eligible patients to participate in research and care programs, and prioritize personalized treatment options.”

Founded in 2018, xCures currently stands at the forefront of innovation in how healthcare technology can benefit both patients with cancer and medical professionals in the field of oncology.

Their xINFORM portal automatically requests all medical records on a patient’s behalf and is integrated with national Electronic Health Information Exchange (HIE) networks. If data is still missing, xCures can query individual providers outside the network to receive complete records. Going far beyond the structured data, the xCures A.I.-powered platform abstracts knowledge from unstructured data such as physician notes and embedded images such as genomics reports.

This means all data, regardless of where it came from, is uniformly structured, in one place, for the convenience of the patient.

In near real-time, a “Care Summary” is generated. Patients can share this up-to-date and accurate information with their medical providers and professionals, making it easy for them to review a patient’s cancer journey and facilitate access to promising trials or alternative treatments. The complete medical records are simultaneously available for use, enabling all participants to have the source data as needed.

xCures’ A.I. matching engine can actively cross-reference a vast library of oncology data to match each patient with the most promising treatment options. Options can be novel or off-label, based on insights from leading experts and predicted outcomes.

Together, these services empower patients and their oncologists to make the most informed and effective treatment decisions throughout their cancer journey.

About xCures:
xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from any institution a cancer patient visited and organizes them into a powerful care summary. This summary greatly facilitates the generation of treatment options reports and connects cancer patients and their physicians with optimal approved or investigational therapies. The platform’s portals, xINFORM for patients and xDECIDE for providers, provide scientific and medical rationales for any treatment options. The platform prospectively generates Real-time Regulatory-grade Clinical (RRC) Data for studies and decentralized trials. For more information, contact info@xcures.com.

xCures partners with mProbe, to leverage their targeted proteomics platform for profiling individual patients’ cancer tissues for actionable drug targets

xCures, Inc. is proud to announce their collaboration with mProbe Inc., a premier CLIA-certified targeted proteomics company. mProbe utilizes a proprietary technology platform integrating artificial intelligence and multi-omic diagnostics to transform the diagnosis, prevention, and treatment of complex diseases such as cancer.

As the knowledge of cancer and its treatments advance, it is ever more apparent that every cancer is unique. Through this collaborative partnership, xCures and mProbe will work toward helping cancer patients better understand their tumors’ molecular profile at the proteomic level, allowing precision diagnostics to guide precision medicines by selecting the most effective cancer treatment regimens. mProbe uses a pathologist guided laser microdissection platform to isolate tumor areas from formalin fixed paraffin embedded (FFPE) tissue followed by multiplex mass spectrometry-based quantification of targets for chemotherapy, targeted therapy and immunotherapy.  The clinical proteomics test is marketed as OncoOmicsDx.

By integrating xCures’ rich real-world longitudinal clinical data with mProbe’s cancer proteomics panels, the two companies are working to expedite the discovery of predictive, diagnostic, and prognostic biomarkers for cancer.

“We are thrilled to partner with mProbe and to leverage their OncoOmicsDx platform for profiling cancer tissues for patients on our platform,” said Mika Newton, CEO of xCures. “We hope our combined efforts towards identifying and expanding upon precision-based actionable drug targets will help cancer patients find the best treatments for their unique cancers.”

“When mProbe and xCures join forces in the fight against advanced cancer by offering integrated treatment plans which leverage targeted proteomics, precision diagnostics,  artificial intelligence, and predictive modeling, we are giving hope to advanced cancer patients who have exhausted the standard of care.” said Peter Chen, CEO of mProbe.  “With this new collaboration, we will be able to provide oncologists with actionable proteomic information to help them make informed decisions,” said Dr. Sheeno Thyparambil, Ph.D.,  Senior Director of R&D at mProbe. 

About xCures

xCures Inc. operates an AI-assisted platform that helps cancer patient aggregate, organize, and structure all their medical data into an easy-to-use Care Summary. The Care Summary greatly facilitates the generation of a Treatment Options Report, and connects cancer patients and their physicians, with optimal investigational or approved therapies.

The platform’s portals, xINFORM for patients, and xDECIDE for providers, show scientific and medical rationales for any treatment options provided. The platform prospectively generates Real-time Regulatory-grade Clinical Data for studies and decentralized trials. For more information, contact info@xcures.com.

About mProbe

mProbe Inc.is a leading biotechnology company based in Palo Alto, California is committed to promoting human health in the fields of precision diagnostics and healthcare analytics.  mProbe has developed a proprietary technology platform integrating artificial intelligence and multi-omic approach to transform the disease diagnosis, prevention, and treatment paradigm. For more information, please visit www.mprobe.com.

Oblato’s first-in-class small molecular OKN-007 will be available through a newly opened compassionate use protocol.

xCures, Inc., a clinical study platform provider, and Oblato, Inc., a biotechnology company, are pleased to announce the availability of OKN-007 through an intermediate size expanded access program (iEAP) for eligible patients with pediatric diffuse midline glioma (DMG), inclusive of diffuse intrinsic pontine glioma (DIPG). Oblato is currently developing OKN-007 as a treatment for glioblastoma multiforme (GBM).

Pediatric diffuse gliomas are rare but have a very poor prognosis, and current treatment options show little benefit. Because pre-clinical research and emerging clinical data support the potential for OKN-007 in this population and the life-threatening nature of malignant gliomas including DIPG, Oblato is making OKN-007 available to qualified physicians through the iEAP.

“xCures is pleased to continue our efforts to bring pre-approval access to investigational medications for pediatric cancer patients. We are excited about the underlying science behind OKN-007 and the opportunity to use our platform to generate evidence and accelerate OKN-007 development. Our platform offers an efficient solution for physicians and patients seeking access to promising therapies when clinical trials are not an option,” says Mika Newton, CEO of xCures. “xCures’ has a track record of delivering high-value real-world evidence from expanded access programs.”

Ki -Hong Ahn, CEO of Oblato comments, “We are pleased that xCures will serve as the partner for the iEAP. With the new protocol now in place, we look forward to initiating this important program for pediatric cancer patients. We will expand the investigation into OKN-007 for DMG and DIPG patients as well as GBM patients.”

This treatment protocol (NCT05518838) is now available. Interested patients or physicians can learn more at xcures.com/details/okn007/.

About Expanded Access:
Expanded access, which is often called “compassionate use,” is the use of an unapproved drug for treatment of patients with serious or life-threatening illnesses outside of a clinical trial. Expanded access is subject to oversight from the US FDA in accordance with the regulations outlined in 21 CFR 312.305.

About Oblato:
Oblato, Inc., a wholly-owned subsidiary of the Korean biotech company HLB Therapeutics, is incorporated in Delaware and has its principal place of business in New Jersey. Since 2016, the Company has been developing a new drug, OKN-007, to treat brain cancers, especially, GBM as a rare disease and DIPG as a rare pediatric disease. Currently, clinical trials are ongoing to investigate the safety and efficacy of a combination therapy with both OKN-007 and temozolomide for patients with both newly diagnosed and recurrent GBM. Oblato has received both rare pediatric disease and fast track designations for DIPG. For additional information about Oblato, please visit www.oblatoinc.com.

About xCures:
xCures Inc. provides clinical study platforms that use AI/ML algorithms to support tumor boards with the allocation of cancer patients to optimal treatment programs and clinical trials. The xCures platform prospectively generates Real World Evidence for investigational and approved therapies. Patient EMR data is continuously collected, stored, and structured into a regulatory-grade format that is ready for use in submissions to the FDA. For more information, contact info@xcures.com.

This was first released on EINPresswire

xCures and Vault Health integration creates a decentralized platform to benefit pancreatic cancer research and facilitate enrollment in Faeth’s NEAAR-001 study

xCures, Inc. is proud to partner with Vault Health, a decentralized research and workforce screening company, to facilitate the enrollment of pancreatic cancer patients in Faeth Therapeutics’ NEAAR-001 research study. NEAAR-001 is a clinical trial of a precision nutrition-based diet that restricts specific amino acids that preclinical studies suggest are necessary for cancer growth. The study involves patients with recently diagnosed metastatic pancreatic adenocarcinoma who are scheduled to receive chemotherapy treatment with gemcitabine and abraxane.

Vault Health’s decentralized research capabilities will allow Faeth to extend the NEAAR clinical trial beyond physical clinical trial sites to patients living across the country. By combining xCures’ records collection, virtual screening, eConsent and data structuring technology with Vault Health’s state-of-the-art suite of patient-centric clinical research services, including telemedicine, remote sample collection, and logistics, the NEAAR-001 protocol can be delivered directly to patients in the convenience of their homes.

“We are thrilled to partner with Vault Health and Faeth Therapeutics to help recently diagnosed pancreatic cancer patients access the NEAAR-001 study as a patient-centric and decentralized clinical trial,” said Mika Newton, CEO of xCures. “Importantly, our combined efforts will enable cancer patients from diverse populations and socioeconomic backgrounds to participate in research.”

“We are excited to bring our patient-first philosophy to simplify the journey and offer clinical research as a care option to pancreatic cancer patients,” said Alexander Pastuszak, MD, PhD, President of Clinical Care and Chief Medical & Scientific Officer, Vault Health. “Together with xCures and Faeth Therapeutics, we are looking forward to rapidly recruiting and enrolling patients where they are, reducing recruitment timelines and costs, and increasing patient engagement.”

“Faeth is dedicated to curing every cancer for every patient, and this partnership with Vault Health and xCures will make it easier for many more people with metastatic pancreatic cancer to access our precision nutrition intervention,” said Faeth co-founder and CEO Anand Parikh. “Faeth would like to offer access to our clinical trials to a wider subset of patients, and by enabling remote access to the NEAAR-001 study, they can enroll in our trial without having to leave home, regardless of where they’re based.”

This was first published on EINPresswire

About xCures
xCures Inc. operates an AI-assisted platform that connects cancer patients and physicians with optimal investigational or approved therapies. The platform’s portals, xINFORM for patients, and xDECIDE for providers, show scientific and medical rationales for the options provided and a clear picture of a patient’s medical records and history. The platform prospectively generates real-world evidence for clinical studies and decentralized trials. For more information, contact info@xcures.com.

About Vault
Vault is at the forefront of simplifying the execution of decentralized and hybrid clinical trials and providing the highest quality patient experience, supported by state-of-the-art technology and virtual care. Vault’s mission is to accelerate better health outcomes through faster diagnosis, innovative clinical research and digital-first care delivery. Vault works with more than 3,000 world-class customers – including corporate, public health, education, pharma and biotech – to deliver care to their populations. Learn more: https://www.vaulthealth.com/

About Faeth
Faeth Therapeutics is a cancer metabolism company developing clinically-tested nutrition control, therapeutics, and digital tools for the treatment of cancer. Founded in 2019 by leading researchers in Europe and the United States and backed by leading investors, the company is pioneering its work in cancer metabolism to support a radically new way to treat cancer. Faeth’s research, published in peer-reviewed scientific journals, shows that tailoring the right diet to the cancer patient can significantly impact the efficacy of clinically tested therapeutics for cancer. Feed the fight. For further information: www.faeththerapeutics.com

Decentralized clinical trial for patients with advanced carcinomas helps determine their cancer’s response to specific drugs

[EIN Presswire, July 19, 2022] xCures, Inc. is proud to announce their partnership with Travera, and the launch of a decentralized clinical trial that provides patients with advanced carcinoma a functional profile of their cancer cells. Advanced carcinoma patients often have malignant fluid drained to provide symptomatic relief. Travera’s unique technology takes advantage of this fluid to screen the response of the live tumor cells against approved anti-cancer therapies. 

“We are excited to partner with Travera and leverage the application and clinical utility of their incredible technology,” said Mika Newton, CEO of xCures. “This study will provide many important outcomes, giving patients and their physicians insight into the cancer’s response to various drugs from a screening panel, eventually helping clinical and treatment decision-making.”

The study (TraveraRTGx) will run as a hybrid decentralized research trial utilizing a CLIA-approved test, meaning that the results will be communicated to the physicians and their patients. It will be open to anyone with carcinoma and malignant fluid (pleural effusion, ascites, etc.), most commonly patients with breast cancer, lung cancer, or abdominal cancers. When patients enroll in the study, xCures will work with treating physicians and institutions to ensure the excess fluid is properly stored and sent to Travera, where cancer cells in the fluid will be screened against candidate drugs relevant to the specific patient or cancer type. 

“We are thrilled to partner with xCures and expand the clinical applications of our unique screening technology based on cancer cells’ growth response to candidate drugs,” states Clifford Reid, Travera’s CEO.” Tumor cells in this often discarded malignant fluid can provide critical information about which drugs to prescribe.”

Advanced carcinoma patients and their caregivers interested in the study can register and learn more at https://xcures.com/details/advanced-carcinoma/

About Travera

Travera assists oncologists in selecting treatments for their patients with our revolutionary cancer therapy guidance test that predicts which cancer drugs are most likely to be effective for each cancer patient.  Using a disruptive single-cell measurement technology invented at MIT that measures the ex vivo growth response of live tumor cells to candidate drugs, Travera has overcome the problems that have prevented the many previous generations of therapy guidance tests from being effective in clinical practice. Travera’s 2-day Rapid Therapy Guidance™ test enables patients who are running out of therapeutic options to discover additional options and continue their battle against cancer.  

About xCures

xCures Inc. operates an AI-assisted platform that connects cancer patients and physicians with optimal investigational or approved therapies. The platform’s portals, xINFORM for patients, and xDECIDE for providers, show scientific and medical rationales for the options provided and a clear picture of a patient’s medical records and history. The platform prospectively generates real-world evidence for clinical studies and decentralized trials. For more information, contact info@xcures.com or visit www.xcures.com.

Innovative collaboration focused on developing the first comprehensive Quality of Life dataset for glioblastoma patients

[EIN PressWire June 21, 2022] xCures, Inc., is proud to announce their partnership with Novocure with the intent to develop the first comprehensive, longitudinal Quality of Life (QoL) dataset for glioblastoma (GBM) patients. The alliance between both oncology companies will leverage xCures’ novel, patient-centric platform and deep connections to GBM patient and provider communities through direct engagement with GBM patients, unique partnerships with advocacy groups such as the Musella Foundation, and the offering of valuable services such as cancer history structuring and treatment options research.

“We are delighted to team up with Novocure and see our extensive real-world data from GBM patients applied towards developing a time series analysis of QOL in GBM,” said Mika Newton, CEO of xCures. “As a patient-centric company, we look forward to the outputs of this partnership and to seeing how they improve Quality of Life for those with this devastating cancer.”

Participants enrolled in xINFORM are invited weekly to complete the EuroQol 5-Dimension (EQ-5D-5L) QoL survey. The survey results provided by patients will allow for time series analysis of QoL in GBM. Over the coming year, Novocure and xCures will generate QoL data for 250 patients and integrate it with regulatory-compliant longitudinal outcomes data.

About xCures

xCures Inc. operates an AI-assisted platform that connects cancer patients and physicians with optimal investigational or approved therapies. The platform’s portals, xINFORM for patients, and xDECIDE for providers, show scientific and medical rationales for the options provided and a clear picture of a patient’s medical records and history. The platform prospectively generates real-world evidence for clinical studies and decentralized trials. For more information, contact info@xcures.com.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Headquartered in Jersey, and with a growing global footprint, Novocure has regional operating centers in Root, Switzerland, Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter. Novocure is a registered trademark of Novocure GmbH.

The new collaboration focuses on improving outcomes by continuous learning from every patient’s journey across diverse datasets

CHICAGO, IL, UNITED STATES, June 3, 2022 /EINPresswire/ 

Today, at the annual meeting of the American Society of Clinical Oncology (ASCO), Prognos Health and xCures announced a collaboration to enable real-world data access and insights for life science companies across multiple use cases.  The multi-year agreement will enable linking and access to xCures de-identified data and Prognos healthcare data marketplace.

“We are excited about combining our respective capabilities to improve outcomes and drive powerful insights on gaps in care, therapy impact, and real-world patient outcomes in oncology,” said Mika Newton, CEO of xCures. “We are focused on finding the right treatment for cancer patients and together we believe we can help accelerate that goal.”

“Collaborating with xCures is a great example of how Prognos is solving for disconnected, siloed data that cannot interoperate and leaves an incomplete view of the patient, said Sundeep Bhan, founder and CEO of Prognos. “Providing the ability to combine patients’ data across all data types including lab, claims, pharmacy, EHR, mortality, and SDoH data is critical to improving patient outcomes in Oncology.”

Prognos and xCures utilize Datavant’s Encrypted Token Technology, which enables HIPAA-compliant linking of de-identified patient records to exchange data seamlessly and securely throughout the Datavant ecosystem of partners.

About Prognos Health

Prognos Health is the leading clinically focused data and analytics platform company. The Prognos Factor® platform has the power to query billions of fully integrated lab and health records on more than 325 million de-identified patients to answer or uncover key healthcare questions in minutes, not months. Leveraging the company’s patent-pending technology Prognos enables the agile exchange of integrated, patient-centric data between key healthcare stakeholders directly from the Prognos Marketplace.

About xCures

xCures Inc. operates an AI-assisted platform that connects cancer patients and physicians with optimal investigational or approved therapies. The platform prospectively generates real-world evidence for clinical studies and decentralized trials. For more information, visit www.xcures.com or contact info@xcures.com.

Members of CDRC will be able to utilize xCures’ technology to quickly abstract and structure clinical data to support drug repurposing studies in rare cancer.

xCures today announced has joined the Critical Path Institute’s (C-Path) Cure Drug Repurposing Collaboratory (CDRC). CRDC is operated by C-Path as a public-private partnership with the U.S. Food and Drug Administration (FDA), and the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH).

CDRC’s mission is to facilitate the advancement of drug repurposing, through the use of real-world outcomes data, especially for diseases of high unmet medical need and where there is little financial incentive to develop new drugs. This includes the systematic collection and assessment of the use of existing FDA approved drugs used to treat diseases and conditions that are not on the existing label.

CDRC members are now able to use xCures’ AI-powered software to enable abstraction and mapping of raw data from print or electronic health records (EHR) into a 21 CFR 11 compliant electronic database. xCures’ software platform enables clinical researchers in academic or industry settings to quickly process large volumes of unstructured medical records, and map those to an industry standard clinical data model that utilizes standard biomedical dictionaries and ontologies, while preserving links to source data. This solution substantially reduces the time required to collect and process clinical research data, including data from clinical trials and registries.

By joining the CDRC, xCures empowers consortium members to increase the speed and quality of abstracted clinical data to support exploratory and pivotal studies of repurposed drugs, particularly for rare cancers, including angiosarcoma, a rare cancer affecting the lining of blood vessels.

“By joining the CDRC, we are excited to deploy our EHR-to-EDC solution to catalyze the development of real-world data that can advance and support the identification of safe and effective treatments for rare cancers,” said Mark Shapiro, COO of xCures. “Empowering rare cancer researchers with high-quality, longitudinal clinical data will provide evidence supporting clinical and regulatory decision-making.”

CDRC members include partnerships with international rare cancer patients, researchers, government institutions, and regulators. “We are excited that xCures is joining CDRC,” said Marco Schito, Ph.D., CDRC Executive Director. “This partnership will enable CDRC members researching rare cancers to access state-of-the-art tools to facilitate clinical evidence generation using real-world data.”

The goal will be to develop infrastructure to identify existing generic drugs used to treat rare diseases, which can become candidates for drug repurposing efforts. Deidentified data, in the form of case reports, would be made available publicly.

Patients and physicians interested in the xCures platform may create new accounts via the following link: https://enroll.xcures.com.

For more information about CRDC visit, https://c-path.org/programs/cdrc/.

About xCures

xCures Inc. operates an AI-assisted platform that connects cancer patients and physicians with information about treatment options generated from ongoing collection and processing of health records. The platform prospectively generates regulatory grade real-world data for clinical studies and decentralized trials. For more information or to learn more about xCures’ technology, contact: info@xcures.com.

About C-Path
Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and hundreds of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona, C-Path in Europe is headquartered in Amsterdam, Netherlands and C-Path Ltd. operates from Dublin, Ireland with additional staff in multiple other locations. For more information, visit www.c-path.org.

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 54.2% funded by the FDA/HHS, totaling $13,239,950, and 45.8% funded by non-government source(s), totaling $11,196,634. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.

xCures to use tumor sequencing information and its platform to pair patients with available treatment options

Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, and xCures, a company that aims to improve cancer outcomes and accelerate cancer research using artificial intelligence, today announced a partnership that gives patients enrolling in Endeavor’s clinical trials access to the xCures platform to find the best available treatment options suited to their individual tumor profile. The partnership helps identify patients whose cancers harbor the PTCH1 mutation and may be eligible for Endeavor’s clinical trial. The xCures platform also enables patients to find more suitable treatment options if they are ineligible.

“Endeavor’s partnership with xCures aligns with our patient-first focus and will help guide any patients with cancer who contact us to find the best treatment options for them,” said Anita DiFrancesco, Vice President of Clinical Operations at Endeavor BioMedicines. “We recently dosed the first patient in a Phase 2 study evaluating ENV-101 (taladegib), a small molecule inhibitor of the Hedgehog signaling pathway, in patients with advanced solid tumors harboring PTCH1 loss of function mutations. Endeavor and xCures will work together to identify PTCH1 mutations while also providing alternative treatment options for patients who are ineligible for our trials.”

Patients will be registered on the xINFORM platform. Once a patient is registered, xCures will review their cancer history.  For patients without molecular profiling, xCures will assist patients with tumor sequencing. After the genomic information is added to a patient’s profile, they will receive a report that lists the best treatment options based on their cancer history and their genomic profile. If the patient has the PTCH1 mutation, they and their physician will be made aware of the option to enroll in the Endeavor clinical trial.  Patients whose tumors are negative for the PTCH1 mutation will receive a personalized list of treatment options that they should discuss with their oncologist.

“xCures is pleased to partner with Endeavor to help improve outcomes for cancer patients by helping them understand their treatment options and support them and their physician with access,” said Bryan Federowicz, Vice President of Clinical Operations at xCures. “This partnership is an example of how collaboration between industry, doctors and patients can provide the best, uniquely tailored medicine for each individual patient.”

ENV-101: Targeting the Hedgehog Signaling Pathway in Oncology and Fibrosis

ENV-101 (taladegib), an orally available small molecule inhibitor of the Hedgehog signaling pathway, has already demonstrated preliminary clinical efficacy and safety in nearly 200 subjects enrolled across six completed studies. Initially targeted for a broad group of patients with basal cell carcinoma (BCC), Endeavor is now investigating precision therapy approaches for ENV-101 in multiple types of cancers driven by oncogenic driver mutations in PTCH1, as well as in idiopathic pulmonary fibrosis (IPF).

PTCH1 oncogenic driver mutations in the Hedgehog signaling pathway are found in approximately 2% of all cancers. Because of its prevalence across multiple types of cancer, Endeavor plans to enroll patients in a tumor agnostic study that includes any patient with oncogenic hedgehog mutations irrespective of tissue of origin. Endeavor is currently enrolling patients in an open label Phase 2 clinical trial in oncology (www.clinicaltrials.gov identifier NCT05199584).

For more information about our clinical trial please contact us at: EBMClinical@endeavorbiomedicines.com or call us at 858-727-3199.

About xCures

xCures operates a precision oncology platform that includes direct-to-patient and direct-to-physician portals. The platform uses Artificial Intelligence/Machine Learning algorithms and Natural Language Processing to identify the most promising treatment options for advanced cancer patients.

The platform supports tumor boards and captures valuable data to help accelerate the development of promising new cancer drugs, expand the approved uses of existing drugs, and demonstrate value for reimbursement.

About Endeavor BioMedicines

Endeavor BioMedicines is a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases, including oncology and fibrosis. We combine advancements in technology with an evolving understanding of terminal diseases to develop best-in-class medicines with the potential to reverse the most severe health conditions. Our lead program, ENV-101, is a Hedgehog signaling inhibitor with demonstrated clinical activity that we are investigating in multiple cancers and in IPF. At Endeavor, we are a highly qualified, innovative and focused team that has come together to live up to our name and bold mission: to help patients feel better and live longer. Please visit us on our website at www.endeavorbiomedicines.com and on our LinkedIn and Twitter pages.

Media Contact
Ingrid Mezo, Account Director
ingrid.mezo@canalecomm.com
301-473-2881

Oncologist and cancer educator Dr. Sanjay Juneja will host xCures’ informative podcast on cancer and technology

February 17, 2022 – Oakland, CA. – xCures, a direct-to-patient, and direct-to-physician oncology platform, is proud to announce Sanjay Juneja, MD, as the host to their TARGET: Cancer podcast. Dr. Sanjay Juneja is a leading oncologist and cancer educator with a significant following on social media as ‘TheOncDoc’. By focusing on innovative approaches to deal with cancer, the podcast aims to be a helpful asset to patients who are looking for new solutions.

Cancer remains a greatly feared diagnosis, with more than one out of every three men and women being diagnosed with cancer during their lifetimes. However, current technological and medical advances allow cancer patients to live fruitful and active lives. To inform podcast listeners about the most recent cancer technology, Dr. Juneja will talk to leading experts in cancer treatment and discuss the latest solutions so that audiences worldwide can learn and understand.  

“I have been active and successful on TikTok and Instagram where I quickly realized people have a strong desire to learn more about cancer. I have often been asked to start a podcast and after speaking to Mika Newton and learning more about xCures, I felt I needed to do this,” said Dr. Juneja. “I have always believed in the importance of educating people about cancer, and this podcast is a great way of doing it.”

With over 500,000+ followers on social media, Dr. Juneja is known as ‘TheOncDoc’ across social media platforms, including Instagram, TikTok, YouTube, and Facebook. He has been featured in The Washington Post, regional news channels (PBS, CBS, NBC, NPR), and on social media for MTV, PureWow, DailyMail, and Dr. Mike.

Dr. Juneja was initially scheduled to be a guest on xCures’ TARGET: Cancer Podcast. As a community oncologist, he felt that xCures provided a much-needed service to cancer patients in community practices across the country and was thrilled with the opportunity to host the podcast.

“Sanjay’s energy and desire to educate is inspiring,” said Mika Newton, CEO of xCures. “I am super excited that he is taking over as our host and can’t wait to see what he has in store.”

Previous TARGET: Cancer podcast episodes featured interviews with medical professionals and stories from other cancer patients. Future TARGET: Cancer podcasts will continue to be highly educational – it is the podcast where technology meets oncology. Now hosted by Dr. Juneja, the TARGET: Cancer podcast will have its own YouTube Channel and can be listened to on Spotify and Apple Podcasts.

• Web: https://xcures.com/target-cancer-podcast/ 
• YouTube: https://www.youtube.com/channel/UCLwc0OCtzYJGpHZF4_opo_w
• Spotify: https://open.spotify.com/show/2xMG5y5gOoIut5Ykvm63XO 
• Apple Podcasts: https://podcasts.apple.com/us/podcast/target-cancer-podcast/id1593087681 

About Sanjay

Dr. Sanjay Juneja is a triple board-certified Hematologist & Medical Oncologist serving as Chief of Oncology Service at Baton Rouge General Hospital. He is also a Founding Medical Partner of Doctorpedia.com where he serves as Chief Medical Officer of the Oncology Channel. 

Dr. Juneja is a published co-author in medical journals and has partnered nationally with the American Cancer Society, BeTheMatch, Leukemia & Lymphoma Society, and the Community Oncology Alliance. He was the Keynote Speaker for Canada’s Young Adults with Cancer’s national survivor conference in 2021 and was awarded Business Report’s Forty under 40 as the only physician recipient of the 2021 class. Dr. Juneja has a passion for education and believes that the knowledge gained through collaboration between patients and professionals is essential to empower healthier and more confident lives.

• TikTok: https://www.tiktok.com/@theoncdoc 
• Instagram: https://www.instagram.com/theoncdoc 
• YouTube: https://www.youtube.com/channel/UCItU-qchG3b0doM1tAaRHDw 
• Facebook: https://www.facebook.com/sanjayjunejaMD/ 

About xCures

xCures operates a precision oncology platform that includes direct-to-patient and direct-to-physician portals. The platform uses Artificial Intelligence/Machine Learning algorithms and Natural Language Processing to identify the most promising treatment options for advanced cancer patients. 

The platform supports tumor boards and captures valuable data to help accelerate the development of promising new cancer drugs, expand the approved uses of existing drugs, and demonstrate value for reimbursement. For more information, visit www.xcures.com or contact info@xcures.com.

– 240 million Americans can play a vital role in the search for a vaccine or treatment by contributing critical data from home –

SAN FRANCISCO – April 15, 2020 – xCures, a health technology company focused on the use of artificial intelligence, has released preliminary data from the company’s Behavior, Environment, And Treatments for COVID-19 (BEAT19) registry study, NCT04321811.  The study is designed to enable everyday people, regardless of their health status, to contribute directly to the development of coronavirus treatments. Since the approval of the BEAT19 registry by the Genetic Alliance’s independent review board (IRB) and program launch on March 29, BEAT19 has collected more than 6,000 daily surveys representing people across all 50 US states and several countries. The preliminary data demonstrated that BEAT19 can collect data from patients who are infected with COVID-19 while they are undergoing quarantine and provide clinical researchers with important insights into disease progression.

Most people will combat and recover from COVID-19 in their homes, isolated from their friends and family. Much of the information being collected today by the healthcare system when a person is interacting with their care team, leaving most data until that point unreported. BEAT19 is a way to learn about what is happening to the millions of people who experience COVID-19 outside a hospital. The BEAT19 data will be used to define the natural history of infection and to look for patterns, formulate and test hypotheses. For example, do people with high blood pressure who contract COVID-19 and take an ACE inhibitor fare better than people who take a beta blocker?

“The BEAT19 online trial has the potential to improve our understanding of COVID-19 and help public health experts make evidence-based decisions,” said Vikash Mansinghka, PhD, principal research scientist and principal investigator of the MIT Probabilistic Computing Project. “The data could inform critical research decisions, smooth the path for developing a vaccine, and reveal potential therapeutic options for COVID-19 patients and the healthcare professionals caring for them.”

“Our team has taken an initial look at the BEAT19 data and were able to quickly screen for anomalies. As BEAT19 enrollment grows, we may be able to identify early signals about risk factors and clinical presentations that can be confirmed or corrected by doctors,” added Ulrich Schaechtle, PhD, xCures-MIT BEAT19 collaboration research lead and MIT Probabilistic Computing Project scientist.  “The ability to rapidly assess the data accumulated in the registry means researchers can account for additional factors in their research for a vaccine and treatment, which is critical as the world races to find a solution for the millions of people affected by the COVID-19 pandemic.”

BEAT19 is designed to capture how people are feeling and learn from their experiences during COVID-19.  To really understand the infection, it is necessary to start tracking symptoms before people are diagnosed, to establish a baseline.  During the illness, many BEAT19 participants are taking medications for their ongoing conditions and some appear be taking novel treatments, such as Hydroxychloroquine (HCQ) + azithromycin. The registry is gathering and analyzing real-time information from real people about their daily COVID-19-related experiences. This approach is a proven and very efficient way to generate real-world effectiveness data on emerging therapies that can help guide clinical research.

“The ability to effectively crowd-source data in an effort to solve a global pandemic is proof of the impact health technology and innovation can have on our world,” said Erica Frank, MD, MPH, FACPM, Professor and Canada Research Chair in Preventive Medicine and Population Health, University of British Columbia:  “While the threat of COVID-19 continues, people can participate in finding a cure while practicing physical distancing and sheltering at home.  People-powered research can move faster than traditional approaches and bring together significant new insights from different areas of expertise to solve a massive global health problem.  It’s truly inspiring, and we are proud to volunteer for this effort.”

People, regardless of their current health status, can join BEAT19 by completing a simple enrollment survey and agreeing to participate through the study’s website. The data collected is de-identified to keep the data secure and private, then it is made available as a resource for researchers. As more biopharmaceutical companies begin researching COVID-19 vaccines and therapies, they need to access to vital disease-progression information that is usually only captured by care providers.

“In this unprecedented time, we need to move with urgency to focus resources where they will help people immediately,” said Mika Newton, chief executive officer of xCures, Inc. “Simply put, we knew researchers needed more and early data about COVID-19.  Our team recognized the possibility to apply our experience in accelerating clinical research to the battle at hand, and that doing this quickly could save many lives. The sooner we can answer the many open and important questions about COVID-19, the sooner we can get to our new normal. There is no cost to participate, and registrants can be proud that they acted and played their part in the clinical research needed to combat COVID-19. Together let’s Beat19!”

To join the fight against COVID-19, please visit the BEAT19 registry website at www.BEAT19.org  where you can find out more information about the study and can register to participate as a contributor or request information as a researcher.

About the BEAT19 Registry Study

BEAT19 is a people-powered study, registered on clinicaltrials.gov, designed to understand the natural history of the coronavirus infection before, during and after symptoms, and to understand how pre-existing conditions, medications, and other factors affect disease progression. The BEAT19 registry is used to gather knowledge about new treatments faster than can be done in clinical trials. Participants are everyday people, who might or might not have COVID-19. They all provide confidential data, using a short daily survey sent via email.

If new knowledge (a signal) emerges from the data, then participants whose data contributed to the signal may be contacted for approval to request additional information. This is only done if the knowledge merits deeper exploration.

For more information, or to participate in the study, please visit https://beat19.org/.

About xCures

xCures is a health technology and services company that operates an AI-assisted precision medicine platform that continuously learns from the experiences of all patients, on all treatments, all the time. The platform can determine the best individualized treatment options and services for patients, including access via reimbursement, clinical trials, and expanded-access support. By tightly integrating research and clinical care, xCures enables physicians to make better treatment decisions, patients to achieve superior outcomes, and bio-pharmas to slash the time and cost of developing drugs.